Clinical Trials Search
Clinical Trial 18950
Cancer Type: Malignant Hematology
Interventions:BMS-936558 (Nivolumab); Nivolumab
Study Type: Treatment
Phase of Study: Phase I
- Frederick Locke
A Phase I/Ib Study of Ipilimumab or Nivolumab in Patients with Relapsed Hematologic Malignancies after Allogeneic Hematopoietic Cell Transplantation
This phase I/Ib trial studies the side effects and best dose of ipilimumab or nivolumab in treating patients with cancers of the blood and blood-forming tissues (hematologic cancers) that have returned after a period of improvement (relapsed) after donor stem cell transplant. Monoclonal antibodies, such as ipilimumab and nivolumab, may interfere with the ability of cancer cells to grow and spread.
Primary Objectives: - Phase I: To determine the maximum tolerated dose (MTD) of ipilimumab or nivolumab administered to patients with relapsed hematologic malignancies following allogeneic stem cell transplantation (alloSCT). - Phase Ib: To characterize the toxicity of ipilimumab or nivolumab administered at the MTD. Secondary Objectives: - To assess response rate. - To assess progression free and overall survival. Exploratory Objectives: - To assess the phenotypic and functional effects of ipilimumab or nivolumab on immune cells.